Shorter venetoclax courses in unfit AML
Give venetoclax for 7 or 14 days per cycle instead of 28 to cut infections and low blood counts without losing the benefit.
Cytopenias and infections are the main cause of early death on venetoclax-azacitidine. Retrospective and small prospective series show similar remission rates with 14-day or 7-day venetoclax after the first cycle.
Pages like this
not linked directly; found by shared links- PairingVenetoclax + hypomethylating agent
Shares Decitabine + cedazuridine (oral), VIALE-A, Azacitidine, Venetoclax.
- TrialASCERTAIN-V
Shares Decitabine + cedazuridine (oral), Venetoclax, Acute myeloid leukaemia.
- CompanyTaiho Oncology (Otsuka)
Shares Decitabine + cedazuridine (oral), Acute myeloid leukaemia.
- Key paperVIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy
Shares VIALE-A, Azacitidine, Venetoclax, Older and multimorbid patients are excluded and undertreated.
- TermTumour lysis syndrome (TLS)
Shares VIALE-A, Venetoclax, Acute myeloid leukaemia.
- TermHypomethylating agents (azacitidine, decitabine)
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- IdeaDose-finding in older and frail patients, not extrapolation from fit ones
Shares Older and multimorbid patients are excluded and undertreated, Wrong doses, Acute myeloid leukaemia.
- IdeaA mandatory over-70s cohort with geriatric assessment in every pivotal trial
Shares Older and multimorbid patients are excluded and undertreated, Wrong doses.